Stanford University
Showing 331-340 of 2,442 Results
-
Xiaoke Chen
Associate Professor of Biology
Current Research and Scholarly InterestsOur goal is to understand how brain circuits mediate motivated behaviors and how maladaptive changes in these circuits cause mood disorders. To achieve this goal, we focus on studying the neural circuits for pain and addiction, as both trigger highly motivated behaviors, whereas, transitioning from acute to chronic pain or from recreational to compulsive drug use involves maladaptive changes of the underlying neuronal circuitry.
-
Ying-Li Chen
Assistant Director, Business Development and Strategic Marketing, Office of Technology Licensing (OTL)
BioYing-Li Chen is an Assistant Director, Business Development and Strategic Marketing and manages a team ranging from associates to interns at the Stanford Office of Technology Licensing (OTL). She joined OTL in 2019 and established the Business Development and Marketing Team to lead the technology marketing and public relations efforts. She connects industry partners with inventors to commercialize Stanford’s research and innovation through licensing, strategic alliances, and industry sponsored research. She has more than 11 years of experience in technology commercialization and entrepreneurship at Stanford University, University of California, San Francisco, and Johns Hopkins University.
-
Alan G. Cheng, MD
Edward C. and Amy H. Sewall Professor in the School of Medicine, Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsActive Wnt signaling maintains somatic stem cells in many organ systems. Using Wnt target genes as markers, we have characterized distinct cell populations with stem cell behavior in the inner ear, an organ thought to be terminally differentiated. Ongoing work focuses on delineating the developing significance of these putative stem/progenitor cells and their behavior after damage.
-
Edward C. Cheng
Affiliate, FSI
BioDr. Edward C. Cheng is a technology strategist and visionary leader. He serves as Senior Advisor for the cross-industry Safe AI Agents Consortium Group, whose members include Anthropic, Cohere, Meta, Microsoft, Oracle, PayPal, DoorDash, PwC, Inquiryon, and others. He is also the Chief Technology Officer and Executive Chairman of Inquiryon. Previously, Edward served as VP of AI at Oracle NetSuite and held senior leadership roles at HP.
Edward is the lead inventor of the Log-Structured Merge Tree (LSM Tree), a foundational data structure that enables low-latency, high-throughput, and high-velocity data processing. It is widely adopted by major data management systems across industry, including Google, Meta, X, Microsoft, Oracle, Hadoop, Cassandra, MongoDB, RocksDB, and many others.
His work on Safe AI Agents focuses on governance frameworks, human-centric AI principles, and multi-agent systems that align autonomous AI with democratic values and human oversight. He collaborates across academia, industry, and civil society to advance research, publish scholarly work, and help shape emerging best practices for safe and trustworthy AI agent development and deployment. He also speaks globally about the impacts and risks of AI agents and AGI with diverse communities.
Edward writes under the pen name Edward Sizhe on topics spanning faith, technology, and life purpose. His books include "AI and God," "Journey of Life or Death," and "Five Questions Toward Enriching the Meaning and Purpose of Life, available on Kindle and Amazon."
His research interests include AI agents, distributed big data systems, machine learning and deep learning, parallel search algorithms, high-performance computing, and distributed systems. He is also interested in biblical studies and archaeological evidence surrounding biblical events. Edward has published numerous scientific papers and holds multiple patents in AI, machine learning, and database systems. He previously worked with the Stanford Database Research Group and now serves as Senior Advisor and researcher at the Stanford Deliberative Democracy Lab.
Edward received his PhD in Computer Science from the University of London, his master’s degree from UC Berkeley, and an MBA from Columbia University. -
Paul Cheng MD PhD
Assistant Professor of Medicine (Cardiovascular Medicine)
BioDr. Cheng is a Cardiologist at Stanford University School of Medicine in the Department of Medicine and a member of the Cardiovascular Research Institute. Dr. Cheng received his BEng in Chemical Engineering and BSc in biology at MIT. He subsequently completed his MD/PhD at UCSF working in the Srivastava lab studying how extracellular morphogenic signals affect cardiac development and fate determination of cardiac progenitors. Dr. Cheng completed internal medicine residency and cardiology fellowship at Stanford, including a post-doctoral training in the Quertermous lab. His current clinical focus is in amyloidosis and cardio-oncology.
Dr. Cheng pioneered the application of single cell transcriptomic and epigenetic techniques to study human vascular diseases including atherosclerosis and aneurysm, and applied these techniques to investigate molecular mechanisms behind genetic risk factors for several human vascular diseases including atherosclerosis, and aortopathies such as Marfan's and Loey-Dietz syndrome. The Cheng lab takes a patient-to-bench-to-bedside approach to science. The lab focuses on elucidating new pathogenic mechanisms of human vascular diseases through combing human genetics and primary vascular disease tissues, with high-resolution transcriptomic and epigenetic profiling to generate novel hypothesis that are then tested in a variety of in vitro and in vivo models. The lab is focused on two broad questions: (1) understanding the biological underpinning of the differences in diseases propensities of different arterial segments in an individual (i.e. why do you have atherosclerosis and aneurysms in certain segments but not others), and (2) understanding the role of perivascular fibroblast in human vascular diseases.
Find out more about what the Cheng lab is up to, check out https://chenglab.stanford.edu
